Sample records for polyox wsr-fra polyox

  1. Paroxetine hydrochloride controlled release POLYOX® matrix tablets: Screening of formulation variables using Plackett-Burman screening design

    Microsoft Academic Search

    Shun-Ji Jin; Yeon-Hee Yoo; Min-Soo Kim; Jeong-Soo Kim; Jeong-Sook Park; Sung-Joo Hwang

    2008-01-01

    The aim of the present study was to screen the effects of the formulation variables — POLYOX® molecular weight (X1), the ratio of POLYOX®\\/Avicel® PH102 (X2) and the amount of POLYOX® and Avicel® PH102 (X3), hardness (X4), HPMCP amount (X5), Eudragit® L100 amount (X6), and citric acid amount (X7) — on the paroxetine hydrochloride release from POLYOX® matrix tablet using

  2. Paroxetine hydrochloride controlled release POLYOX matrix tablets: screening of formulation variables using Plackett-Burman screening design.

    PubMed

    Jin, Shun-Ji; Yoo, Yeon-Hee; Kim, Min-Soo; Kim, Jeong-Soo; Park, Jeong-Sook; Hwang, Sung-Joo

    2008-03-01

    The aim of the present study was to screen the effects of the formulation variables - POLYOX molecular weight (X1), the ratio of POLYOX/Avicel PH102 (X2) and the amount of POLYOX and Avicel PH102 (X3), hardness (X4), HPMCP amount (X5), Eudragit L100 amount (X6), and citric acid amount (X7) - on the paroxetine hydrochloride release from POLYOX matrix tablet using the Plackett-Burman screening design. Paroxetine hydrochloride matrix tablets were prepared according to a 7-factor-12-run statistical model and subjected to a 8-h dissolution study in Tris buffer at pH 7.5. The regression results showed that POLYOX molecular weight (X1) and POLYOX/Avicel PH102 ratio (X2) had significantly influence on the drug release mechanism and drug release rate as main effects. Hardness (X4) had an insignificant effect on the drug release mechanism but a significant effect on the drug release rate. On the other hand, HPMCP, Eudragit L100 and citric acid had an insignificant effect on the both responses. The information obtained by screening design study can be expected to be useful for further formulation studies. PMID:18409056

  3. Lift and Drag Measurements on a Hydrofoil in Dilute Polyox Solutions

    Microsoft Academic Search

    Turgut Sarpkaya

    1973-01-01

    THE use of hydrofoils for a wide variety of purposes such as propeller blades on boats, as sailboat keels, ship rudders, submarine and torpedo fins, lifting surfaces of hydrofoil boats, and shroud ring stabilizers for missiles, has prompted efforts to increase the lift-to-drag ratio by various means. The favourable drag reducing effect of polymers, particularly for flows in pipes1, suggests

  4. Optimization Studies on Compression Coated Floating-Pulsatile Drug Delivery of Bisoprolol

    PubMed Central

    Jagdale, Swati C.; Bari, Nilesh A.; Kuchekar, Bhanudas S.; Chabukswar, Aniruddha R.

    2013-01-01

    The purpose of the present work was to design and optimize compression coated floating pulsatile drug delivery systems of bisoprolol. Floating pulsatile concept was applied to increase the gastric residence of the dosage form having lag phase followed by a burst release. The prepared system consisted of two parts: a core tablet containing the active ingredient and an erodible outer shell with gas generating agent. The rapid release core tablet (RRCT) was prepared by using superdisintegrants with active ingredient. Press coating of optimized RRCT was done by polymer. A 32 full factorial design was used for optimization. The amount of Polyox WSR205 and Polyox WSR N12K was selected as independent variables. Lag period, drug release, and swelling index were selected as dependent variables. Floating pulsatile release formulation (FPRT) F13 at level 0 (55?mg) for Polyox WSR205 and level +1 (65?mg) for Polyox WSR N12K showed lag time of 4?h with >90% drug release. The data were statistically analyzed using ANOVA, and P < 0.05 was statistically significant. Release kinetics of the optimized formulation best fitted the zero order model. In vivo study confirms burst effect at 4?h in indicating the optimization of the dosage form. PMID:24367788

  5. An experimental study of non-Newtonian polymer rheology effects on oil recovery and injectivity

    SciTech Connect

    Gleasure, R.W.; Phillips, C.R. (Univ. of Toronto, Toronto (CA))

    1990-11-01

    Pseudoplastic non-Newtonian polymer solutions were examined for their enhanced oil recovery performance. Detailed results are reported for xanthan gum (XAN), Kelzan XCD, and a viscoelastic polyethylene oxide (PEO), Polyox OF-50. Increases in the power-law coefficient resulted in improved displacement efficiency. Effects were also observed in the injectivity-index parameter results.

  6. Influence of plasticizers on the stability and release of a prodrug of ? 9-tetrahydrocannabinol incorporated in poly (ethylene oxide) matrices

    Microsoft Academic Search

    Sridhar Thumma; Mahmoud A. ElSohly; Shuang-Qing Zhang; Waseem Gul; Michael A. Repka

    2008-01-01

    The objective of this research was to stabilize a heat-labile novel prodrug of ?9-tetrahydrocannabinol (THC), THC-hemiglutarate (THC-HG), in polyethylene oxide (PEO) [PolyOx® WSR N-80 (PEO N-80), MW 200,000 Daltons] polymeric matrix systems produced by hot-melt fabrication for systemic delivery of THC through the oral transmucosal route. For this purpose, the effects of processing conditions (processing temperature and heating duration), plasticizer

  7. Design of a novel bilayered gastric mucoadhesive system for localized and unidirectional release of lamotrigine

    PubMed Central

    Mohana Raghava Srivalli, K.; Lakshmi, P.K.; Balasubramaniam, J.

    2012-01-01

    Lamotrigine is a BCS class II drug with pH dependent solubility. The bilayered gastric mucoadhesive tablets of lamotrigine were designed such that the drug and controlled release polymers were incorporated in the upper layer and the lower layer had the mucoadhesive polymers. The major ingredients selected for the upper layer were the drug and control release polymer (either HPMC K15M or polyox) while the lower MA layer predominantly comprised of Carbopol 974P. A 23 full factorial design was constructed for this study and the tablets were optimized for parameters like tablet size, shape, ex vivo mucoadhesive properties and unidirectional drug release. Oval tablets with an average size of 14 mm diameter were set optimum. Maximum mucoadhesive bond strength of 79.3 ± 0.91 * 103 dyn/cm2 was achieved with carbopol when used in combination with a synergistic resin polymer. All the tested formulations presented a mucoadhesion time of greater than 12 h. The incorporation of methacrylic polymers in the lower layer ensured unidirectional drug release from the bilayered tablets. The unidirectional drug release was confirmed after comparing the dissolution results of paddle method with those of a modified basket method. Model independent similarity and dissimilarity factor methods were used for the comparison of dissolution results. Controlled drug release profiles with zero order kinetics were obtained with polyox and HPMC K15M which reported t90% at 6th and 12th hours, respectively. The “n” value with polyox was 0.992 and that with HPMC K15M was 0.946 indicating an approximate case II transport. These two formulations showed the potential for oral administration of lamotrigine as bilayered gastric mucoadhesive tablets by yielding highest similarity factor values, 96.06 and 92.47, respectively, between the paddle and modified basket method dissolution release profiles apart from reporting the best tablet physical properties and maximum mucoadhesive strength. PMID:24109205

  8. Systematic screening of compressed ODT excipients: cellulosic versus non-cellulosic.

    PubMed

    Al-Khattawi, Ali; Iyire, Affiong; Dennison, Tom; Dahmash, Eman; Bailey, Clifford J; Smith, Julian; Rue, Peter; Mohammed, Afzal R

    2014-01-01

    The successful development of compressed ODTs utilises low compression forces to create a porous structure whereby excipients are added to enhance wicking/swelling action or provide strength to the fragile tablet framework. In this work, a systematic investigation comparing materials from two different categories was employed to understand their functionality in binary mixture tablets of the most commonly used diluent mannitol. Cellulose based excipients such as HPC (SSL-SFP), L-HPC (NBD-022) and MCC (Avicel PH-102) were compared with non-cellulosic materials such as PEO (POLYOX WSR N-10) and Crospovidone (XL-10). Pure excipient properties were studied using Heckel Plot, compressibility profile, SEM and XRPD, whereas the prepared binary mixture compacts were studied for hardness, disintegration time and friability. Results from our investigation provide insight into differences encountered in product performance of ODT upon inclusion of additional materials. For example, non-cellulosic excipients Polyox and Crospovidone showed higher plasticity (Py values 588 and 450MPa) in pure form but not in binary mixtures of mannitol. Cellulosic excipients, nonetheless, offer faster disintegration (<30 sec) specifically L-HPC and MCC tablets. Disintegration time for tablets with fully substituted-HPC was prolonged (200-500 sec) upon increasing concentration between 1-10% due to gelation/ matrix formation. It can be concluded that despite the reasonably good plasticity of both cellulosic and noncellulosic excipients in pure form, the mechanical strength in binary mixtures is negatively impacted by the fragmentation/ fracture effect of mannitol. PMID:24655059

  9. Investigating the cubosomal ability for transnasal brain targeting: In vitro optimization, ex vivo permeation and in vivo biodistribution.

    PubMed

    Abdelrahman, Fatma Elzahraa; Elsayed, Ibrahim; Gad, Mary Kamal; Badr, Ahmed; Mohamed, Magdi Ibrahim

    2015-07-25

    The aim of this study was to enhance the risperidone delivery to the brain through the transnasal route via optimization of cubosomal gel. Cubosomes were prepared using glycerol mono-oleate (GMO), Pluronic F127 (PF127) and Tween 80 (T80). The prepared formulae were characterized by testing their particle size, polydispersity index, zeta potential, entrapment efficiency, in vitro drug release and transmission electron microscopy. Central composite design was planned for the formulae optimization and the selected formula (containing PF127 with concentration 15mg/g GMO and T80 with concentration of 20mg/L) was re-prepared in presence of gelling polymer (gellan gum or polyox). The optimal cubosomal gel (containing 0.4% w/v polyox) had been subjected to ex-vivo permeation, histopathological evaluation and in vivo biodistribution studies. It showed significantly higher transnasal permeation and better distribution to the brain, when compared to the used control (drug solution and/or suspension). Finally, the cubosomal gel could be considered as a promising carrier for brain targeting of CNS acting drugs through the transnasal route. PMID:26026251

  10. Formulation Optimization of Hot Melt Extruded Abuse Deterrent Pellet Dosage Form Utilizing Design of Experiments (DOE)

    PubMed Central

    Maddineni, Sindhuri; Battu, Sunil Kumar; Morott, Joe; Majumdar, Soumyajit; Repka, Michael A.

    2014-01-01

    The objective of the present study was to develop techniques for an abuse-deterrent (AD) platform utilizing hot melt extrusion (HME) process. Formulation optimization was accomplished by utilizing Box-Behnken design of experiments to determine the effect of the three formulation factors: PolyOx™ WSR301, Benecel™ K15M, and Carbopol 71G; each of which was studied at three levels on TR attributes of the produced melt extruded pellets. A response surface methodology was utilized to identify the optimized formulation. Lidocaine Hydrochloride was used as a model drug, and suitable formulation ingredients were employed as carrier matrices and processing aids. All of the formulations were evaluated for the TR attributes such as particle size post-milling, gelling, percentage of drug extraction in water and alcohol. All of the DOE formulations demonstrated sufficient hardness and elasticity, and could not be reduced into fine particles (<150µm), which is a desirable feature to prevent snorting. In addition, all of the formulations exhibited good gelling tendency in water with minimal extraction of drug in the aqueous medium. Moreover, Benecel™ K15M in combination with PolyOx™ WSR301 could be utilized to produce pellets with TR potential. HME has been demonstrated to be a viable technique with a potential to develop novel abuse-deterrent formulations. PMID:24433429

  11. Influence of processing parameters and formulation factors on the bioadhesive, temperature stability and drug release properties of hot-melt extruded films containing miconazole.

    PubMed

    Chen, Meiwan; Lu, Jiannan; Deng, Weibin; Singh, Abhilasha; Mohammed, Noorullah Naqvi; Repka, Michael A; Wu, Chuanbin

    2014-06-01

    This study investigated the processing parameters and formulation factors on the bioadhesive properties, temperature stability properties, and drug release properties of miconazole in PolyOx® and Klucel® matrix systems produced by Hot-melt Extrusion (HME) technology. Miconazole incorporated into these matrix systems were found to be stable for 8 months by X-ray diffraction (XRD). The addition of miconazole increased area under the curve (AUC) at contact time intervals of 30 and 60 sec, while the bioadhesion decreased with an increase in processing temperatures. The release profiles suggest that a sustained release of miconazole was observed from all of the tested HME film formulations for approximately 10 h. The release from the optimal HME film extruded at 205°C was found to be significantly different than that extruded at 190°C. Therefore, this matrix system may address the present shortcomings of currently available therapy for oral and pharyngeal candidiasis. PMID:24550099

  12. Formulation and evaluation of floating tablet of H2-receptor antagonist.

    PubMed

    Kesarla, Rajesh S; Vora, Pratik Ashwinbhai; Sridhar, B K; Patel, Gunvant; Omri, Abdelwahab

    2014-09-22

    Abstract Context: Conventional sustained dosage form of ranitidine hydrochloride (HCl) does not prevent frequent administration due to its degradation in colonic media and limited absorption in the upper part of GIT. Objectives: Ranitidine HCl floating tablet was formulated with sublimation method to overcome the stated problem. Methods: Compatibility study for screening potential excipients was carried out using Fourier transform infrared spectroscopy (FT-IR) and differential scanning chromatography (DSC). Selected excipients were further evaluated for optimizing the formulation. Preliminary screening of binder, polymer and sublimating material was based on hardness and drug release, drug release with release kinetics and floating lag time with total floatation time, respectively. Selected excipients were subjected to 3(2) factorial design with polymer and sublimating material as independent factors. Matrix tablets were obtained by using 16/32" flat-faced beveled edges punches followed by sublimation. Results: FT-IR and DSC indicated no significant incompatibility with selected excipients. Klucel-LF, POLYOX WSR N 60?K and l-menthol were selected as binder, polymer and sublimating material, respectively, for factorial design batches after preliminary screening. From the factorial design batches, optimum concentration to release the drug within 12?h was found to be 420?mg of POLYOX and 40?mg of l-menthol. Stability studies indicated the formulation as stable. Conclusion: Ranitidine HCl matrix floating tablets were formulated to release 90% of drug in stomach within 12?h. Hence, release of the drug could be sustained within narrow absorption site. Moreover, the dosage form was found to be floating within a fraction of second independent of the pH of media ensuring a robust formulation. PMID:25243639

  13. Design and Development of Polyethylene Oxide Based Matrix Tablets for Verapamil Hydrochloride

    PubMed Central

    Vidyadhara, S.; Sasidhar, R. L. C.; Nagaraju, R.

    2013-01-01

    In the present investigation an attempt has been made to increase therapeutic efficacy, reduced frequency of administration and improved patient compliance by developing controlled release matrix tablets of verapamil hydrochloride. Verapamil hydrochloride was formulated as oral controlled release matrix tablets by using the polyethylene oxides (Polyox WSR 303). The aim of this study was to investigate the influence of polymer level and type of fillers namely lactose (soluble filler), swellable filler (starch 1500), microcrystalline cellulose and dibasic calcium phosphate (insoluble fillers) on the release rate and mechanism of release for verapamil hydrochloride from matrix tablets prepared by direct compression process. Higher polymeric content in the matrix decreased the release rate of drug. On the other hand, replacement of lactose with anhydrous dibasic calcium phosphate and microcrystalline cellulose has significantly retarded the release rate of verapamil hydrochloride. Biopharmaceutical evaluation of satisfactory formulations were also carried out on New Zealand rabbits and parameters such as maximum plasma concentration, time to reach peak plasma concentration, area under the plasma concentration time curve(0-t) and area under first moment curve(0-t) were determined. In vivo pharmacokinetic study proves that the verapamil hydrochloride from matrix tablets showed prolonged release and were be able to sustain the therapeutic effect up to 24 h. PMID:24019567

  14. Coal log pipeline pilot plant study

    SciTech Connect

    Liu, H.; Lenau, C.W.; Burkett, W.

    2000-07-01

    After 8 years of extensive R and D in the new technology of coal log pipeline (CLP), a pilot plant is being built to demonstrate and test a complete CLP system for coal transportation. The system consists of a coal log fabrication plant, a 3,000-ft-length, 6-inch-diameter underground pipeline loop to transport 5.4-inch diameter coal logs, a log injection/ejection system, a pump bypass, a reservoir that serves as both the intake and the outlet of the CLP systems, an instrumentation system that includes pressure transducers, coal log sensors, and flowmeters, and an automatic control system that includes PLCs and a central computer. The pilot plant is to be completed in May of Year 2000. Upon completion of construction, the pilot plant will be used for running various types of coal, testing the degradation rate of drag reduction in CLP using Polyox (polyethylene oxide), testing the reliability of a special coal log sensor invented at the University of Missouri, testing the reliability and the efficiency of the pump-bypass system for pumping coal log trains through the pipe, and testing various hardware components and software for operating the pilot plant. Data collected from the tests will be used for designing future commercial systems of CLP. The pilot plant experiments are to be completed in two years. Then, the technology of CLP will be ready for commercial use.

  15. Design and in vitro evaluation of a novel vaginal drug delivery system based on gelucire.

    PubMed

    Geeta, M Patel; Madhabhai, M Patel

    2009-04-01

    Carbamazepine indicated for the control of epilepsy, undergoes extensive hepatic first-pass metabolism after oral administration. A vaginal dosage form of carbamazepine is not commercially available. Conventional suppository having poor retention in the vaginal tract, as they are removed in a short time by the tract's self-cleansing action, having poor patient compliance. To overcome such problems, delivery system with mucoadhesive polymers polyox WSR N-60K and Ucarflock 302 that prolong drug permanence on the vaginal mucosa were developed. In the present study the suitability of gelucires to formulate vaginal pesseries was investigated. The possible modification of carbamazepine release kinetics by using gelucires blends and hydrophilic additives in the pesseries was evaluated. It was observed that among gelucire grades melting point higher than 37 degrees C, the release rate proved to be highly dependant on HLB value and matrix composition. In most of the formulations carbamazepine release occurred by disintegration and erosion of the matrices which is depending upon the vehicle employed. The aging study revealed that the formulations containing G50/13 and G50/13-G44/14 blends undergo some changes during one year of shelf aging. From the results obtained it can be concluded that different gelucire grades and their blends along with hydrophilic polymer could be successesively used to formulate prolong release carbamazepine pesseries. PMID:19450222

  16. Influence of Plasticizers on the Stability and Release of a Prodrug of ?9-Tetrahydrocannabinol Incorporated in Poly (Ethylene Oxide) Matrices

    PubMed Central

    Thumma, Sridhar; ElSohly, Mahmoud A.; Zhang, Shuang-Qing; Gul, Waseem; Repka, Michael A.

    2008-01-01

    The objective of the present research was to stabilize a heat-labile novel prodrug of ?9-tetrahydrocannabinol (THC), THC-hemiglutarate (THC-HG), in polyethylene oxide (PEO) [PolyOx® WSR N-80 (PEO N-80), MW 200,000 Daltons] polymeric matrix systems produced by hot-melt fabrication for systemic delivery of THC through the oral transmucosal route. For this purpose, the effects of processing conditions (processing temperature and heating duration), plasticizer type and concentration and storage conditions on the stability of the prodrug were investigated. The selected plasticizers studied included vitamin E succinate (VES), acetyltributyl citrate (ATBC), triethyl citrate (TEC), triacetin and polyethylene glycol 8000 (PEG 8000). Furthermore, the influence of plasticizer concentration on drug release was also studied. The stability of THC-HG in PEO matrices was influenced by all of the aforementioned variables. Films processed at 110 °C for 7 min were found to be favorable for hot-melt processing with a post- processing drug content of 95%, while significant degradation of THC-HG (~42%) was observed in those processed at 200 °C for 15 min. The degradation of the prodrug during hot-melt fabrication and also upon storage was considerably reduced in the presence of the plasticizers investigated, VES being the most effective. Modulation of the microenvironmental pH to an acidic range via incorporation of citric acid in PEO-plasticizer matrices significantly improved the stability of the prodrug, with almost 90% of the theoretical drug remaining as opposed to only 15% remaining in PEO-only matrices when stored at 40 °C for up to 3 months. The release of drug from PEO matrices was influenced both by the plasticizer type and concentration. A faster release resulted from water-soluble plasticizers, PEG 8000 and triacetin, and with increasing concentration. However, a slower release was observed with an increase in concentration of water-insoluble plasticizers, VES and ATBC. PMID:18602993

  17. Formulation and evaluation of micro hydrogel of Moxifloxacin hydrochloride.

    PubMed

    Nanjwade, Basavaraj K; Deshmukh, Rucha V; Gaikwad, Kishori R; Parikh, Kemy A; Manvi, F V

    2012-06-01

    The field of ocular drug delivery is one of the interesting and challenging endeavors facing the pharmaceutical scientist. Novel approaches for ophthalmic drug delivery need to be established to increase the ocular bioavailability by overcoming the inherent drawbacks of conventional dosage forms. In situ hydrogels are instilled as drops into the eye and undergoes a sol-to-gel transition in the cul-de-sac, improved ocular bioavailability by increasing the duration of contact with corneal tissue, thereby reducing the frequency of administration. The purpose of the present work was to develop an ophthalmic drug delivery system using three different gelling agents with different mechanisms for in situ gelation of Moxifloxacin hydrochloride, a fluoroquinolone antibiotic. polyox (a pH-sensitive gelling agent), sodium alginate (an ion-sensitive gelling agent), and poloxamer (a temperature-sensitive gelling agent) were employed for the formation of in situ hydrogel along with HPMC K4M as viscofying agent, which increases the residence time of the drug in the ocular cavity. The promising formulations MF(4), MF(5), and MF(9) were evaluated for pH, drug content, in vitro gelation, in vitro drug release, in vivo drug release, ocular irritation, and stability. Percent drug content of 98.2, 98.76, and 99.43%; viscosity of 15.724 × 100, 16.108 × 100, and 15.213 × 100 cP at 20 rpm, cumulative percent release of 75.364, 74.081, and 71.752%, and C (max) of 1,164.16, 1,187.09, and 1,220.58 ng/ml was observed for formulation MF(4), MF(5), and MF(9), respectively. The developed formulations were therapeutically efficacious, stable, and non-irritant and provided sustained release of the drug over 8 h. PMID:22015966